Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.

Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA.

JAMA Oncol. 2018 Aug 2. doi: 10.1001/jamaoncol.2018.2969. [Epub ahead of print]

PMID:
30073261
2.

Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.

Guibert N, Tsukada H, Hwang DH, Chambers E, Cibas ES, Bale T, Supplee J, Ulrich B, Sholl LM, Paweletz CP, Oxnard GR.

Lung Cancer. 2018 Aug;122:72-75. doi: 10.1016/j.lungcan.2018.05.024. Epub 2018 May 25.

PMID:
30032849
3.

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays.

Oxnard GR, Paweletz CP.

JAMA Oncol. 2018 Jul 19. doi: 10.1001/jamaoncol.2018.2311. [Epub ahead of print] No abstract available.

PMID:
30027282
4.

Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.

Camidge DR, Sequist LV, Jänne PA, Weickhardt AJ, Dowling ES, Alicea J, Fan J, Oxnard GR.

Clin Lung Cancer. 2018 May 5. pii: S1525-7304(18)30097-4. doi: 10.1016/j.cllc.2018.04.015. [Epub ahead of print]

PMID:
29861396
5.

Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR.

Kuang Y, O'Connell A, Sacher AG, Feeney N, Alden RS, Oxnard GR, Paweletz CP.

Methods Mol Biol. 2018;1768:193-207. doi: 10.1007/978-1-4939-7778-9_12.

PMID:
29717445
6.

False-Positive Plasma Genotyping Due to Clonal Hematopoiesis.

Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, Guibert NM, Awad MM, Wong KK, Jänne PA, Paweletz CP, Oxnard GR.

Clin Cancer Res. 2018 Mar 22. doi: 10.1158/1078-0432.CCR-18-0143. [Epub ahead of print]

PMID:
29567812
7.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

J Clin Oncol. 2018 Jun 1;36(16):1631-1641. doi: 10.1200/JCO.2017.76.8671. Epub 2018 Mar 5.

PMID:
29504847
8.

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review.

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC.

Arch Pathol Lab Med. 2018 Mar 5. doi: 10.5858/arpa.2018-0901-SA. [Epub ahead of print]

PMID:
29504834
9.

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.

Guibert N, Hu Y, Feeney N, Kuang Y, Plagnol V, Jones G, Howarth K, Beeler JF, Paweletz CP, Oxnard GR.

Ann Oncol. 2018 Apr 1;29(4):1049-1055. doi: 10.1093/annonc/mdy005.

PMID:
29325035
10.

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non-small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations.

Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR.

Clin Cancer Res. 2017 Dec 15;23(24):7467-7473. doi: 10.1158/1078-0432.CCR-17-1447. Epub 2017 Sep 27.

PMID:
28954786
11.

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients.

Hu Y, Alden RS, Odegaard JI, Fairclough SR, Chen R, Heng J, Feeney N, Nagy RJ, Shah J, Ulrich B, Gutierrez M, Lanman RB, Garber JE, Paweletz CP, Oxnard GR.

Clin Cancer Res. 2017 Dec 1;23(23):7351-7359. doi: 10.1158/1078-0432.CCR-17-1745. Epub 2017 Sep 25.

PMID:
28947568
12.

Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review.

Sacher AG, Komatsubara KM, Oxnard GR.

J Thorac Oncol. 2017 Sep;12(9):1344-1356. doi: 10.1016/j.jtho.2017.05.022. Epub 2017 Jun 10. Review.

PMID:
28611011
13.

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM.

J Immunother. 2017 Jul/Aug;40(6):249-251. doi: 10.1097/CJI.0000000000000173.

PMID:
28557813
14.

Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases.

Martínez P, Mak RH, Oxnard GR.

JAMA Oncol. 2017 Sep 1;3(9):1274-1275. doi: 10.1001/jamaoncol.2017.1047. Review.

PMID:
28520828
15.

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.

Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.

Cancer Res. 2017 May 15;77(10):2712-2721. doi: 10.1158/0008-5472.CAN-16-3404. Epub 2017 Mar 31.

16.

Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2017 Feb 17;7:41197. doi: 10.1038/srep41197. No abstract available.

17.

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Sholl LM, Do K, Shivdasani P, Cerami E, Dubuc AM, Kuo FC, Garcia EP, Jia Y, Davineni P, Abo RP, Pugh TJ, van Hummelen P, Thorner AR, Ducar M, Berger AH, Nishino M, Janeway KA, Church A, Harris M, Ritterhouse LL, Campbell JD, Rojas-Rudilla V, Ligon AH, Ramkissoon S, Cleary JM, Matulonis U, Oxnard GR, Chao R, Tassell V, Christensen J, Hahn WC, Kantoff PW, Kwiatkowski DJ, Johnson BE, Meyerson M, Garraway LA, Shapiro GI, Rollins BJ, Lindeman NI, MacConaill LE.

JCI Insight. 2016 Nov 17;1(19):e87062.

18.

Restoring Balance: Paraneoplastic Cerebellar Degeneration.

Klein JP, Stover DG, Oxnard GR, Levy BD, Loscalzo J.

Am J Med. 2017 Mar;130(3):e85-e87. doi: 10.1016/j.amjmed.2016.09.035. Epub 2016 Nov 2. No abstract available.

PMID:
27816447
19.

Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.

Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR.

Cancer Discov. 2016 Dec;6(12):1334-1341. Epub 2016 Sep 30.

20.

Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.

Aerts HJ, Grossmann P, Tan Y, Oxnard GR, Rizvi N, Schwartz LH, Zhao B.

Sci Rep. 2016 Sep 20;6:33860. doi: 10.1038/srep33860. Erratum in: Sci Rep. 2017 Feb 17;7:41197.

21.

Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer.

Oxnard GR, Paweletz CP, Sholl LM.

JAMA Oncol. 2017 Jun 1;3(6):740-741. doi: 10.1001/jamaoncol.2016.2835. No abstract available.

PMID:
27541382
22.

Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.

Lampson BL, Nishino M, Dahlberg SE, Paul D, Santos AA, Jänne PA, Oxnard GR.

Cancer. 2016 Aug 15. doi: 10.1002/cncr.30270. [Epub ahead of print]

23.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S.

J Thorac Oncol. 2016 Oct;11(10):1690-700. doi: 10.1016/j.jtho.2016.05.035. Epub 2016 Jul 25.

24.

Early Intervention in Lung Cancers With Rapid Plasma Genotyping for EGFR and KRAS Mutations-Reply.

Sacher AG, Alden RS, Oxnard GR.

JAMA Oncol. 2016 Aug 1;2(8):1096-7. doi: 10.1001/jamaoncol.2016.1963. No abstract available.

PMID:
27388452
25.

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA.

J Clin Oncol. 2016 Oct 1;34(28):3375-82. doi: 10.1200/JCO.2016.66.7162. Epub 2016 Jun 27.

26.

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA.

Clin Cancer Res. 2016 Dec 15;22(24):6010-6020. Epub 2016 Jun 8.

27.

135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC.

Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Barrett C, Yang J, Jänne P.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S154. doi: 10.1016/S1556-0864(16)30328-8. Epub 2016 Apr 15. No abstract available.

28.

136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial.

Ahn MJ, Yang J, Yu H, Saka H, Ramalingam S, Goto K, Kim SW, Yang L, Walding A, Oxnard GR.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S115. doi: 10.1016/S1556-0864(16)30246-5. Epub 2016 Apr 15. No abstract available.

29.

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR.

JAMA Oncol. 2016 Aug 1;2(8):1014-22. doi: 10.1001/jamaoncol.2016.0173. Erratum in: JAMA Oncol. 2016 Aug 1;2(8):1099.

30.

The cellular origins of drug resistance in cancer.

Oxnard GR.

Nat Med. 2016 Mar;22(3):232-4. doi: 10.1038/nm.4058. No abstract available.

PMID:
26937615
31.

Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH.

JAMA Oncol. 2016 Jun 1;2(6):772-9. doi: 10.1001/jamaoncol.2015.6315.

32.

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM.

J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4.

PMID:
26729443
33.

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer.

Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR.

JAMA Oncol. 2016 Mar;2(3):313-20. doi: 10.1001/jamaoncol.2015.4482.

34.

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.

Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354. Review.

35.

Clinical Implications of Variant ALK FISH Rearrangement Patterns.

Gao X, Sholl LM, Nishino M, Heng JC, Jänne PA, Oxnard GR.

J Thorac Oncol. 2015 Nov;10(11):1648-52. doi: 10.1097/JTO.0000000000000665.

36.

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.

Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA.

J Thorac Oncol. 2015 Dec;10(12):1726-35. doi: 10.1097/JTO.0000000000000687.

37.

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR.

Clin Cancer Res. 2016 Feb 15;22(4):915-22. doi: 10.1158/1078-0432.CCR-15-1627-T. Epub 2015 Oct 12.

38.

Biomarker-driven adjuvant targeted therapy for NSCLC-the ALCHEMIST trials.

Oxnard GR, Watt C, Wigle D, Boughey JC.

Bull Am Coll Surg. 2015 Sep;100(9):25-7. No abstract available.

PMID:
26455072
39.

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.

Alden RS, Mandrekar SJ, Oxnard GR.

Chin Clin Oncol. 2015 Sep;4(3):37. doi: 10.3978/j.issn.2304-3865.2015.09.03. Review.

40.

Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.

Tanizaki J, Ercan D, Capelletti M, Dodge M, Xu C, Bahcall M, Tricker EM, Butaney M, Calles A, Sholl LM, Hammerman PS, Oxnard GR, Wong KK, Jänne PA.

Cancer Res. 2015 Aug 1;75(15):3139-46. doi: 10.1158/0008-5472.CAN-14-3771. Epub 2015 Jun 5.

41.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, Ercan D, Matthews SE, Cantarini M, Barrett JC, Jänne PA, Oxnard GR.

Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4.

42.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR.

N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.

43.

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.

Lo PC, Dahlberg SE, Nishino M, Johnson BE, Sequist LV, Jackman DM, Jänne PA, Oxnard GR.

Cancer. 2015 Aug 1;121(15):2570-7. doi: 10.1002/cncr.29397. Epub 2015 Apr 15.

44.

Commentary.

Oxnard GR.

Clin Chem. 2015 Apr;61(4):586-7. doi: 10.1373/clinchem.2014.234484. No abstract available.

45.

Enhanced ratio of signals enables digital mutation scanning for rare allele detection.

Castellanos-Rizaldos E, Paweletz C, Song C, Oxnard GR, Mamon H, Jänne PA, Makrigiorgos GM.

J Mol Diagn. 2015 May;17(3):284-92. doi: 10.1016/j.jmoldx.2014.12.003. Epub 2015 Mar 13.

46.

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.

Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA.

Clin Lung Cancer. 2015 Sep;16(5):e101-4. doi: 10.1016/j.cllc.2015.01.009. Epub 2015 Feb 7. No abstract available.

47.

Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.

Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA.

Clin Cancer Res. 2015 Jun 15;21(12):2851-60. doi: 10.1158/1078-0432.CCR-14-3112. Epub 2015 Mar 3.

48.

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.

Gerber DE, Oxnard GR, Govindan R.

Clin Pharmacol Ther. 2015 May;97(5):447-50. doi: 10.1002/cpt.91. Epub 2015 Apr 3. Review.

49.

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.

Jänne PA, Ou SH, Kim DW, Oxnard GR, Martins R, Kris MG, Dunphy F, Nishio M, O'Connell J, Paweletz C, Taylor I, Zhang H, Goldberg Z, Mok T.

Lancet Oncol. 2014 Dec;15(13):1433-41. doi: 10.1016/S1470-2045(14)70461-9. Epub 2014 Nov 5.

PMID:
25456362
50.

Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.

Yu HA, Sima CS, Shen R, Kass S, Gainor J, Shaw A, Hames M, Iams W, Aston J, Lovly CM, Horn L, Lydon C, Oxnard GR, Kris MG, Ladanyi M, Riely GJ.

J Thorac Oncol. 2015 Mar;10(3):431-7. doi: 10.1097/JTO.0000000000000432.

Supplemental Content

Loading ...
Support Center